Faricimab (Vabysmo)

Faricimab is a real, FDA-approved bispecific antibody — the first ever built for injection into the eye — that completes this site's anti-VEGF cluster alongside aflibercept, the drug its own pivotal trials were built to match. Approved 28 January 2022 for wet age-related macular degeneration and diabetic macular edema, it blocks two separate blood-vessel-growth pathways at once and matched aflibercept's vision outcomes in head-to-head Phase 3 trials while cutting the number of injections patients need — a real practical win that has since reshaped the eye-injection market, alongside a genuine, still-monitored post-marketing safety signal for eye inflammation.

The first bispecific antibody built for the eye

Wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion all share a common driver: abnormal, leaky blood vessels growing in or under the retina, chiefly stimulated by vascular endothelial growth factor-A (VEGF-A) — the same target this site's aflibercept page describes a fusion-protein "trap" blocking. Faricimab, developed by Genentech/Roche, blocks VEGF-A too, but adds a second, independent binding arm against angiopoietin-2 (Ang-2), a separate protein that destabilizes blood vessels and promotes inflammation through a different pathway. Built as a true bispecific antibody — one molecule with two distinct binding sites, rather than two separate drugs — it was the first bispecific antibody ever approved for intraocular use anywhere, on the theory that blocking two independent drivers of vascular leakage at once would let the eye stay stable for longer between injections than blocking VEGF-A alone.

TENAYA and LUCERNE: matching aflibercept with fewer injections

Faricimab's approval for wet AMD rested on two identically designed Phase 3, double-masked, active-comparator trials, TENAYA and LUCERNE, which randomized a combined 1,329 patients to faricimab (dosed up to every 16 weeks, based on individual disease activity) or aflibercept (a fixed every-8-week schedule). At one year, faricimab produced vision gains statistically non-inferior to aflibercept, and about 45% of faricimab patients across both trials reached the longest, every-16-week dosing interval by the end of year one (Heier JS, Khanani AM, Quezada Ruiz C, et al., "Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials," Lancet 2022;399(10326):729-740, PMID 35085502, DOI: 10.1016/S0140-6736(22)00010-1).¹ The FDA approved faricimab as Vabysmo on 28 January 2022 for wet AMD and diabetic macular edema together, making it the first FDA-approved eye medicine to offer treatment intervals stretching to four months in year one.

YOSEMITE and RHINE: the same story in diabetic macular edema

A parallel pair of identically designed Phase 3 trials, YOSEMITE and RHINE, tested the same faricimab-versus-aflibercept comparison in 1,891 patients with diabetic macular edema, again finding faricimab's individualized dosing — extendable up to every 16 weeks — produced vision gains non-inferior to fixed every-8-week aflibercept, with anatomic measures (retinal fluid resolution) favoring faricimab (Wykoff CC, Abreu F, Adamis AP, et al., "Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials," Lancet 2022;399(10326):741-755, PMID 35085503, DOI: 10.1016/S0140-6736(22)00018-6).² Across both diabetic macular edema trials, roughly half of faricimab patients (52.8% in YOSEMITE, 51.0% in RHINE) reached every-16-week dosing, and about one in five reached every-12-week dosing — real evidence that fewer injections per year, not just non-inferior vision outcomes, was a genuine achievable result for many patients rather than a best-case average.

A third indication, and a real post-marketing safety signal

Current status

Faricimab remains FDA-approved across all three indications and is marketed by Genentech/Roche as Vabysmo; the FDA further updated its label in April 2026 to extend treatment for retinal-vein-occlusion-related macular edema beyond the original 6-month trial window. Its extended-dosing convenience has translated into real market share gains against aflibercept — Regeneron's own 2025 financial disclosures cite Vabysmo's uptake as a driver of falling combined Eylea/Eylea HD US sales, the same shift this site's aflibercept page describes from the opposite side. No faricimab biosimilar exists as of this review, and as an eye-injection biologic administered exclusively by an ophthalmologist in-office, it carries no wellness, cosmetic, or self-administered use of any kind.